Intellectual Property in the Age of Personal Genomics and Synthetic Biology
Christopher M. Holman, Intellectual Property in the Age of Personal Genomics and Synthetic Biology, 31 BIOTECHNOLOGY LAW REPORT 1 (2012).
2 Pages Posted: 17 Apr 2015
Date Written: April 15, 2015
Biotechnology appears poised for fundamental changes that could alter the calculus regarding the role of intellectual property in incentivizing discovery and commercialization. Historically, the most significant products arising out of biotechnology have been recombinantly expressed proteins (including monoclonal antibodies) and row crops modified by the introduction of genes conferring resistance to herbicides, pests, or both. Genetic diagnostic testing has shown clinical utility with respect to a few Mendelian (i.e., single gene) conditions such as cystic fibrosis and BRCA-related cancers, but for the most part continues to play a relatively minor role in healthcare. However, many are looking toward synthetic biology and personal genomics as important developments in the evolution of biotechnology. This editorial provides an overview of some of the important intellectual property issues connected with the rising importance of personal genomics and synthetic biology in biotechnology.
Keywords: patents, intellectual property, biotechnology, genomics, synthetic biology, genetic testing, diagnostic testing
Suggested Citation: Suggested Citation